GENETIC TECHNOLOGIES LIMITED — Investor Presentation 2020

Sep 15, 2020

ASX Market Announcement

==> picture [154 x 51] intentionally omitted <==

Investor Presentation

MELBOURNE, AUSTRALIA, September 16, 2020 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, is pleased to announce that the Company is presenting at the prestigious HC Wainwright 22nd Annual Global Investment Conference attended by some of the leading institutional investors in the health care space and this year conducted by virtual conference.

Please see attached Investor Presentation for the HC Wainwright 22nd Annual Global Investment Conference.

Dr George Muchnicki Acting CEO and Justyn Stedwell Company Secretary Authorised by the Board of Directors Genetic Technologies Limited +61 3 8412 7000

Investor Relations and Media (US)

Dave Gentry, CEO RedChip Companies Office: 1 800 RED CHIP (733 2447) Cell: US 407 491 4498 dave@redchip.com

Australia

Trevor Chappell WE Communications Email: tchappell@we-worldwide.com T: +61 407 933 437

Genetic Technologies Limited www.gtglabs.com info@gtglabs.com ABN 17 009 212 328

60-66 Hanover Street Fitzroy Victoria 3065 Australia +61 3 8412 7000

==> picture [155 x 51] intentionally omitted <==

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.

Genetic Technologies has capacity for COVID-19 testing and is developing a pipeline of risk assessment products.

For more information, please visit www.gtglabs.com.

60-66 Hanover Street Fitzroy Victoria 3065 Australia +61 3 8412 7000

Genetic Technologies Limited www.gtglabs.com info@gtglabs.com ABN 17 009 212 328

==> picture [116 x 38] intentionally omitted <==

==> picture [461 x 150] intentionally omitted <==

NASDAQ: GENE HC Wainwright & Co 22[nd] Annual Global Investment Conference 14-16 September 2020

Forward looking statements

==> picture [116 x 38] intentionally omitted <==

This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited (ACN 009 212 328) and certain of the plans and objectives of its management. These statements are statements that are not historical facts.

Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

q q

q q q

q

Genetic Technologies is a leader in genomics

==> picture [116 x 38] intentionally omitted <==

q

Over a decade of R&D surrounding the development of polygenic risk scores with an extensive Patent Portfolio

Company Snapshot:

• Creator of Laboratory Developed Tests (LDT) supported by proprietary polygenic risk scores (PRS) platform

• Market capitalization as at 10 Sep 2020: US$45.082M - Dual listed on Australia Securities Exchange (ASX) & NASDAQ: GTG.AX, GENE

• CLIA certified and NATA accredited to ISO15189 which allows us to operate in the North American and Australasian Markets

Developing risk prediction platforms for the major causes of mortality in western society

Strong scientific leadership under Dr Richard Allman – in collaboration with - No. Shares on some the world’s most prestigious universities and medical institutes 70% of Float on Nasdaq – 14m ADR’s GeneType Breast Cancer and Colorectal tests are in market with anticipated issue: 8,261,726,743 (ADR @ 600:1) release of Cardiovascular and T2D tests in Q3 CY20 & COVID-19 sdr in Q4 - CY20 Cash position as at 31 August 2020 A$19.2M

70% of Float on Nasdaq – 14m ADR’s issue: 8,261,726,743 (ADR @ 600:1)

CIT Platform Launched Sep 2020 for Consumer Initiated Sales

==> picture [224 x 144] intentionally omitted <==

In 2021 will offer the most comprehensive suite of polygenic risk assessment tests on the market:

3

Polygenic (Genetic) Risk Score

==> picture [116 x 38] intentionally omitted <==

Our Platform

• Most common complex diseases (CCD) are a result of many genes acting in concert

• Polygenic Risk Score is a DNA based risk assessment (screening) tool that weighs a person’s odds of developing a CCD by inspecting the genome (DNA)

• Genomic and non-genomic factors are considered including lifestyle and family history

• Validated risk stratification method = (GWAS)

• Identifies high-risk individuals for low risk and high risk people for personalized precise screening

==> picture [458 x 191] intentionally omitted <==

----- Start of picture text -----

Average Risk
Relative Risk Relative Risk
X 0.2 X 5.0
Polygenic Risk
Frequency
----- End of picture text -----

4

Polygenic Risk Scores (PRS) Platform

==> picture [116 x 38] intentionally omitted <==

Proprietary platform developed over the past decade and supports multiple PRS tests targeting healthy individuals to identify serious disease risk.

• PRS is a DNA based risk assessment tool that weighs a person’s odds of developing common complex disease(s)

• GTG’s proprietary risk stratification platform is based on AI and big data analytics and is internationally validated by genome wide association studies (GWAS)

• Platform supports PRS tests that allow for personalised precise solutions for high, average and low risk individuals and delivers actionable results for those individuals and their physicians – personalized screening, lifestyle solutions, chemoprophylaxis (medical intervention) and surgical intervention, if appropriate

==> picture [96 x 12] intentionally omitted <==

----- Start of picture text -----

Breast Cancer
----- End of picture text -----

==> picture [208 x 168] intentionally omitted <==

==> picture [113 x 9] intentionally omitted <==

----- Start of picture text -----

Mavaddat et al. (2015) JNCI
----- End of picture text -----

==> picture [120 x 11] intentionally omitted <==

----- Start of picture text -----

Colorectal Cancer
----- End of picture text -----

==> picture [310 x 168] intentionally omitted <==

Jenkins et al. (2019) Familial Cancer

==> picture [157 x 11] intentionally omitted <==

----- Start of picture text -----

Cardiovascular disease
----- End of picture text -----

==> picture [229 x 167] intentionally omitted <==

Abraham et al. (2016) Eur Heart J.

5

Product test pipeline and status

==> picture [116 x 38] intentionally omitted <==

• Our platform supports risk predictive testing in major oncological, metabolic, regenerative and infectious disease indications (including COVID-19)

• Our tests in market and development cover up to 70% off causes of morbidity and mortality in the US

• GeneType Breast Cancer and Colorectal tests in market and anticipate market release of Cardiovascular and T2D tests Q3 CY20 and COVID-19 Serious Disease Risk test in Q4 CY20

==> picture [833 x 294] intentionally omitted <==

----- Start of picture text -----

4Q 2019
Breast Cancer
Market Release 1Q 2020
Colorectal Cancer Market Release Cardiovascular Test validation 2Q 2020
Type 2 Diabetes COVID-19 risk of
Test validation 3Q 2020
hospitalisation
Test prototype
Cardiovascular
Prototype 4Q 2020
Type 2 Diabetes Prostate
Market Release
Cancer
COVID-19
Melanoma
Validation &Regulatory
Approval
COVID-19
Market Release 6
----- End of picture text -----

Disease coverage

==> picture [116 x 38] intentionally omitted <==

• Our product development strategy aims to provide coverage of the most significant causes of morbidity and mortality in the US

• It covers up to 70% of causes of mortality

Incidence of underlying causes of mortality in the US

SOURCE: NCHS, National Vital Statistics System, Mortality https://www.cdc.gov/nchs/products/databriefs/db355.htm

==> picture [225 x 209] intentionally omitted <==

Breast Cancer Colorectal Cancer Type 2 Diabetes Cardiovascular Disease Other causes

Data sources: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention, 2019 https://cancerstatisticscenter.cancer.org/?_ga=2.118034377.1123388856.1600219325-238729237.1600219325#!/

7

GTG has developed a world-first polygenic risk test for breast cancer

==> picture [116 x 38] intentionally omitted <==

Easy-to-use test solves the compliance problem

Risk stratification enables precision screening and personalised prevention

==> picture [465 x 248] intentionally omitted <==

----- Start of picture text -----

Breast Cancer Risk Assessment Final Test Report
GeneType for Breast Cancer
Report Issued By:Laboratory Accession Number:Date of Specimen Collection:Date of Laboratory Receipt: Patient MRN:Patient Address:Patient Name:Date of Birth: Ordering Medical Practitioner:
Date of Report:
This patient is at a
POTENTIALLY HIGH risk of breast cancer
2.98 28.12% 12.22%
Patient's PolygenicRisk Score Patient'sLifetime Risk Patient's5 Year Risk
Lifetime Risk 5 Year Risk
≥25%for similar ageand ethnicityAveragePatient'sLifetime Riskrisk Patient'sriskPotentiallyHigh Risk for similar ageand ethnicityAverage risk Patient'srisk
The Polygenicfrequencies and odds ratios.Risk Score is a relative risk calculated as the multiplicative product of the patient's risk alleles weighted according to ethnicity-specific allele
Report continued on next page v2 Nov-2019 Page 1/6
Tested by GeneType Pty(ABN 60 050 029 279)60-66 Hanover StreetFitzroy, Victoria, 3065, AustraliaLtd AccreditedCLIA Number:Laboratory Director: Dr.and ISO 15189 (NATA Accreditation No: 20432)for compliance with99D2023356MichaelNPAACChristieStandards support@genetype.com.auTel +61Fax +613 8412 70003 8412 7040
Simple cheek swab test Report sent to your doctor
----- End of picture text -----

Simple cheek swab that help determine a woman’s risk of developing breast cancer

Identifying 5-year and lifetime risk

Clinically actionable results targeting sporadic breast cancer

Informs screening and health monitoring for those most at risk

Validated for use in caucasian, african american & hispanic women over 35 yr

GeneType’s technology covers up to 85% of breast cancer

8

GTG has developed a world-first polygenic risk test for colorectal cancer

==> picture [116 x 38] intentionally omitted <==

Easy-to-use test solves the compliance problem Risk stratification enables precision screening and personalised prevention Clinically actionable results 5-year, 10-year and lifetime risk Informs screening and health monitoring for those most at risk Simple cheek swab test Report sent to your doctor

GeneType’s technology covers up to 95% of colorectal cancer

9

==> picture [116 x 38] intentionally omitted <==

COVID-19 sdr (serious disease risk)

==> picture [316 x 310] intentionally omitted <==

10

COVID-19 at a glance

• About 30 million confirmed COVID-19 cases worldwide, with a mortality of almost 1 million*

• Pandemic management strategies vary depending on country, but mostly one size fits all approaches

• New Normal = maintaining social restrictions (distancing/isolation) until a vaccine is found; businesses and the economy struggle to recover, mental health emerges as a serious parallel challenge

• COVID-19 vaccine may take another 8-12 months to rollout , unclear timeline, efficacy, safety profile, ease of scaling up production and costs of development

==> picture [116 x 38] intentionally omitted <==

==> picture [401 x 246] intentionally omitted <==

• The coronavirus could cost the global economy more than $2.7 trillion – equivalent to the entire GDP of the UK**

11

• WHO Coronavirus disease (COVID-19) Situation Report – 155 (10 September 2020). **https://www.bloomberg.com/graphics/2020-coronavirus-pandemic-global-economic-risk/

COVID-19 sdr (serious disease risk)

==> picture [116 x 38] intentionally omitted <==

• COVID-19 sdr is Genetic Technology’s COVID-19 Response – a low-cost, accurate assessment tool that is designed to assist in pandemic management in lieu of a vaccine

• It is the world’s first genomic test to predict the risk of hospitalization and of developing life-threatening complications, should the patient contract COVID-19

==> picture [201 x 294] intentionally omitted <==

Simple cheek swab

Assist with risk stratification; designed to improve ongoing pandemic management – protect high-risk, identify low-risk and possibly contribute to a safe herd immunity solution

12

Development Progress To-Date

==> picture [116 x 38] intentionally omitted <==

COVID-19 sdr is designed to enable the targeting of limited vaccine resources to those at highest risk of developing life threatening complications should they contract the virus

==> picture [79 x 79] intentionally omitted <==

==> picture [79 x 79] intentionally omitted <==

==> picture [79 x 79] intentionally omitted <==

The Test is in Beta

• The first clinical kit due in Q3 2020

Fast-tracking development

• In discussions with major international reagent suppliers = > 5 million test a week

• Eligible for fast-tracking with US and Australian regulators Applying for CE mark

Market Release

• Anticipated early Q4 2020

13

==> picture [191 x 122] intentionally omitted <==

• Simple to implement

• Suitable for people aged 30-65

• Designed to identify high risk and low risk individuals

• Can be offered as a priority to first responders, health workers, transport and food supply groups

• Could prioritize early intervention of high risk groups who are infected with COVID-19

• Could be used to prioritize vaccination candidates

• Could be used to safely implement herd immunity in the absence of a safe/effective vaccine candidate

14

Intellectual property is a core advantage

==> picture [116 x 38] intentionally omitted <==

GTG has a strong patent portfolio covering the breast cancer risk assessment test

5 Patents granted in the US

• Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of the core genetic markers included in the BREVAGenplus® risk assessment test

• Patent No. 7,127,355 offering broad protection re: methods of genetic analysis (the concept of combining clinical risk assessment with genetic risk factors to improve predictability over clinical risk assessment alone)

7 Patent families pending

• Methods for breast cancer risk assessment

• Methods for assessing risk of developing breast cancer

• Patent No. 6,969,589 covering the identification of informative SNPs

5 Patents granted in China

• Improved methods for assessing risk of developing breast cancer

• Markers for breast cancer

• Patent Nos. 200680051710.0; 201310524782.4; 201310524916.2 and 201310524765.0 “Markers for Breast Cancer”

• Patent No. 201080033130.5 Methods for Breast Cancer Risk Assessment

5 Patents granted in Hong Kong

• Methods for genetic analysis

• Methods for genomic analysis

• Methods for assessing risk of developing colorectal cancer

• Patent Nos. 09101235.4; 12112875.1; 12112368.5 and 12112874.2 “Markers for Breast Cancer”

• Patent No. 12109000.5 Methods for Breast Cancer Risk Assessment

15

The Next 12 months:

==> picture [116 x 38] intentionally omitted <==

• Complete development of High density multi disease tests covering >70% mortality in western society using a single swab and delivering low cost, accurate risk data.

• Establish new divisions: Oncology, Metabolic diseases, Cardiovascular disease, Mental health (including cognitive decline),pharmacogenomics (Pgx), wellness.

• Commission Next Generation Sequencing (NGS) compete for the relatable monogenic space and combine monogenic and polygenic testing under one integrated service to deliver 100% genetic risk cover.

• Establish a subscription service which will update individuals as to their ongoing disease risk without the need to re-test and for as little as $1 a day.

• • CIT Platform and Telehealth for Consumer Initiated Testing including COVID-19 sdr Test and entire product portfolio

Our board

==> picture [52 x 97] intentionally omitted <==

==> picture [154 x 55] intentionally omitted <==

==> picture [107 x 108] intentionally omitted <==

==> picture [107 x 108] intentionally omitted <==

Dr. Jerzy “George” Muchnicki MBBS Executive Director & Chief Executive Officer (Interim)

==> picture [107 x 108] intentionally omitted <==

==> picture [107 x 108] intentionally omitted <==

Mr. Peter Rubinstein BSc, BEc, LLB Chairman - Non – Executive Director

==> picture [116 x 38] intentionally omitted <==

Dr. Lindsay Wakefield MBBS Non – Executive Director

Mr Nick Burrows

B.Com, FAICD, FCA, FGIA, FTIA, F Fin Non – Executive Director

17